A Mindfulness-based Intervention for Hotel Staff

April 27, 2026 updated by: Jennifer Yee Man Tang, Chinese University of Hong Kong

Mindfulness Training for Hotel Staff: A Mixed-Methods Randomized Controlled Trial

This research aims to investigate the potential impact of a structured mindfulness-based professional development program on hotel employees and to explore why and how these changes occur during and after the mindfulness intervention through a mixed-methods approach. A 6-week mindfulness intervention with 60 hotel staff from a hotel will be implemented in Hong Kong. Both quantitative and qualitative data will be collected to examine changes in job-related outcomes, wellbeing, and state mindfulness and teachers' lived experiences and perspectives associated with this intervention. Data will be analyzed based on convergent parallel mixed-method approach, such as mixed-effects modeling, mediation analysis, and thematic analysis. This study may provide practical implications for developing evidence-based programs to promote wellbeing and service quality among hotel employees.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
60

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Hong Kong
      • Hong Kong, Hong Kong
        • The Chinese University of Hong Kong
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Aged 18 years or above
  • Currently working in a hotel
  • Cantonese speaker
  • Willing to commit time for the 6-week mindfulness course

Exclusion Criteria:

  • Individuals who had previously joined a related group mindfulness-based intervention, such as mindfulness-based cognitive therapy (MBCT), mindfulness-based stress reduction (MBSR), or Mindfulness - Finding Peace in a Frantic World (FPFW)
  • Staff members who are mentally unstable or having active suicidal risk

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: A mindfulness-based intervention
Behavioral: A mindfulness-based intervention
This is a 6-week mindfulness-based program consisting of mindfulness practices, cognitive-behavioral techniques, and other psychological exercises with 6 sessions (1 hour/session)
No Intervention: Waitlist control
It is a waitlist control condition.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Emotional Labor Scale (ELS)
Time Frame: Week 0, Week 6, and Week 10
It is used to measure the emotional labor strategies of participants and the scale contains 11 items organized in two subscales: Surface Acting and Deep Acting. Participants will rate their responses on a 5-point Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). The total score of the Surface Acting subscale ranges from 7 to 35 and the total score of the Deep Acting subscale ranges from 4 to 20. A higher total score on each subscale indicates a higher tendency to use that particular strategy.
Week 0, Week 6, and Week 10
Professional Efficacy Subscale of the Maslach Burnout Inventory- General Survey (MBI-GS)
Time Frame: Week 0, Week 6, and Week 10
It is used to measure participants' professional efficacy. The scale consists of 6 items on a 7-point Likert scale ranging from 0 (never) to 6 (everyday). The total score ranges from 0 to 36. A higher score indicates a higher level of professional efficacy.
Week 0, Week 6, and Week 10
Nature of Work Subscale of Job Satisfaction Survey (JSS)
Time Frame: Week 0, Week 6, and Week 10
It is used to measure participants' job satisfaction. The scale contains 4 items on a 6-point Likert scale from 1 (disagree very much) to 6 (agree very much). The total score ranges from 4 to 24. A higher total score indicates a greater job satisfaction.
Week 0, Week 6, and Week 10

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
The Perceived Stress Scale (PSS-10)
Time Frame: Week 0, Week 6, and Week 10
It is used to measure participants' perceived stress levels. Participates rate their stress on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The total score ranges from 0 to 40. A higher total score indicates higher stress levels.
Week 0, Week 6, and Week 10
The Generalized Anxiety Disorder-7 (GAD-7)
Time Frame: Week 0, Week 6, and Week 10
It is used to measure participants' anxiety symptoms. The scale contains 7 items on a 4-point Likert scale ranging from 0 (not at all) to 3 (nearly every day) over the past two weeks. The total score ranges from 0 to 21. A higher total score indicates a higher level of anxiety.
Week 0, Week 6, and Week 10
Patient Health Questionnaire-9 (PHQ-9)
Time Frame: Week 0, Week 6, Week 10
It is used to measure participants' depressive symptoms. The scale contains 9 items on a 4-point Likert scale ranging from 0 (not at all) to 3 (nearly every day) over the past two weeks. The total score ranges from 0 to 27. A higher total score indicates higher depressive symptoms.
Week 0, Week 6, Week 10
The Chinese version of the State Mindfulness Scale
Time Frame: Week 0, Week 6, and Week 10
It is used to measure participants' state mindfulness. Participants give ratings on a 5-point Likert scale from 1 (not at all) to 5 (very much). The total score ranges from 21 to 105. A higher total score means a higher level of state mindfulness.
Week 0, Week 6, and Week 10

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Chinese University of Hong Kong

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
February 28, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 31, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 15, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 15, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 21, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 30, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 27, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • SBRE-25-0781

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings